Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London
· Delayed Price · Currency is GBP · Price in USD 302.86
-2.88 (-0.94%)
At close: Jun 6, 2025
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,230 employees as of December 31, 2024. The number of employees increased by 130 or 6.19% compared to the previous year.
Employees
2,230
Change (1Y)
130
Growth (1Y)
6.19%
Revenue / Employee
814.98K GBP
Profits / Employee
-93.61K GBP
Market Cap
29.00B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| HUTCHMED (China) | 1,811 |
| Genus | 3,500 |
Alnylam Pharmaceuticals News
- 2 days ago - Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case - Benzinga
- 9 days ago - Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field - Seeking Alpha
- 10 days ago - Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference - Business Wire
- 11 days ago - Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga
- 18 days ago - Alnylam Issues 2024 Corporate Responsibility Report - Business Wire
- 21 days ago - Alnylam posts new Phase 3 data for heart disease therapy Amvuttra - Seeking Alpha
- 21 days ago - AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - Business Wire
- 26 days ago - Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress - Business Wire